Join
Dynavax Technologies Corporation logo

DVAX

NASDAQ

Dynavax Technologies Corporation

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2004
$15.49+0.00 (+0.00%)
News25/Ratings8

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Price$15.49+5.44 (+54.18%)
2025-11-042026-02-09
News · 26 weeks550%
2025-11-09: 02025-11-16: 12025-11-23: 02025-11-30: 02025-12-07: 02025-12-14: 02025-12-21: 12025-12-28: 82026-01-04: 02026-01-11: 12026-01-18: 12026-01-25: 32026-02-01: 22026-02-08: 362026-02-15: 22026-02-22: 02026-03-01: 02026-03-08: 02026-03-15: 02026-03-22: 02026-03-29: 02026-04-05: 02026-04-12: 02026-04-19: 02026-04-26: 02026-05-03: 0
2025-11-092026-05-03
Mix3890d
  • SEC Filings23(61%)
  • Insider13(34%)
  • Other2(5%)

Latest news

25 items

DVAX FAQ

7 questions
  • What does Dynavax Technologies Corporation do?
    Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp &...
  • Where does DVAX stock trade?
    Dynavax Technologies Corporation (DVAX) is listed on NASDAQ.
  • What sector and industry is DVAX in?
    Dynavax Technologies Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Dynavax Technologies Corporation go public?
    Dynavax Technologies Corporation (DVAX) completed its IPO in 2004.
  • What are analysts saying about DVAX?
    Dynavax Technologies Corporation has had 8 recent analyst actions on file. The most recent action was from Goldman: Sell with a $1200.00 price target on 2025-02-11. Recent price targets range from $1200.00 to $3800.00.
  • What companies are similar to DVAX?
    Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare DVAX side-by-side with any of them on Quantisnow.
  • How can I track DVAX on Quantisnow?
    Quantisnow aggregates Dynavax Technologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DVAX to receive live email and push alerts on every new disclosure.